Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma

26 Jan 2021

Abstract excerpt

Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we identified two genes (ANLN and ARNTL2) from multiple gene expression data sets, and developed a two-mRNA-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33585490
DOI: 10.3389/fcell.2021.634697

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung AdenocarcinomaPMID 33585490Read ↗

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosisSemantic proximity Read ↗

Multi‑omics identification of a signature based on malignant cell-associated ligand–receptor genes for lung adenocarcinomaSemantic proximity Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene setsSemantic proximity Read ↗

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinomaSemantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

Exploration of Tumor Mutation Burden Combined with Immune Infiltrates in the Prognosis of Lung AdenocarcinomaSemantic proximity Read ↗

Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genesSemantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Semantic proximity Read ↗

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.Semantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.